Fentanyl is a powerful synthetic opioid used in carefully supervised medical treatment. It can also cause physical dependence, addiction and life-threatening overdose. Pharmaceutical fentanyl and illegally manufactured fentanyl need to be distinguished: the latter accounts for most recent fentanyl-related overdose harms in the United States.
Fentanyl can dangerously slow or stop breathing, especially when used without established opioid tolerance or alongside alcohol or other sedating substances. If someone cannot be awakened or has slow, absent or abnormal breathing, call the local emergency number immediately, give naloxone if available according to its instructions, and stay with them. Further doses may be needed; emergency assessment is still necessary if they improve. Effective treatment and ongoing support are available for opioid addiction.
Fentanyl acts at opioid receptors to relieve pain and can suppress breathing. The CDC describes it as approximately 50 to 100 times more potent than morphine; this is not a safe dosing or conversion rule. Illegally manufactured fentanyl can occur in counterfeit pills or other drugs, and its presence and strength cannot reliably be judged from appearance.
The following names describe different fentanyl formulations, with different indications and restrictions. They are not interchangeable. Availability varies by country and product. In September 2024, the FDA reported that all manufacturers of US transmucosal immediate-release fentanyl (TIRF) medicines were discontinuing production and that patients already receiving treatment could continue while supplies remained. These brand names should therefore not be read as a current list of available treatment choices. See the FDA TIRF update.
Actiq
Actiq is an oral transmucosal lozenge, absorbed through the lining of the mouth between the cheek and gum; it is not a sublingual tablet. Its labeled role is breakthrough cancer pain in patients already receiving regular opioid treatment and meeting the product’s opioid-tolerance requirements.
Abstral
Abstral is a sublingual fentanyl tablet developed for breakthrough cancer pain in adults already receiving maintenance opioid treatment and meeting the product’s opioid-tolerance requirements. It is not suitable for someone who is opioid-naive.
Sublimaze
Sublimaze is an injectable fentanyl formulation used by trained professionals in monitored medical settings, including anesthesia. Its use requires appropriate monitoring and facilities to manage breathing problems.
Subsys
Subsys is a sublingual fentanyl spray developed for breakthrough cancer pain in opioid-tolerant adults. It is not a general treatment for occasional pain and must not be substituted dose-for-dose for another fentanyl product.
Duragesic
Duragesic is a fentanyl skin-patch formulation for severe, persistent pain in appropriately opioid-tolerant patients when other treatment options are inadequate. Fentanyl patches are not for acute or postoperative pain or use as needed. Direct heat can increase fentanyl absorption and cause a fatal overdose; follow the product’s safety instructions.
Lazanda
Lazanda is a nasal fentanyl spray developed for breakthrough cancer pain in adults who are already opioid-tolerant. Cancer treatment alone does not make someone eligible for this medicine.
Opioid use disorder involves a pattern of opioid use causing clinically significant problems. It requires a professional assessment; changes in appearance, mood or finances alone do not establish the diagnosis. Features that may warrant assessment include:
- Repeatedly taking more opioids or using them for longer than intended
- Unsuccessful attempts to reduce or control opioid use
- Strong cravings or substantial time spent obtaining, using or recovering from opioids
- Difficulty meeting important responsibilities because of opioid use
- Continuing use despite related health or relationship problems
- Using opioids in hazardous circumstances
Physical dependence and tolerance can occur during prescribed opioid treatment and do not, by themselves, establish opioid use disorder. Drowsiness, dizziness, nausea, constipation and itching can occur with fentanyl. The following are urgent safety concerns rather than ordinary signs of addiction:
- Slow, absent or abnormal breathing, inability to wake, or blue or gray lips: call emergency services immediately and give naloxone if available according to its instructions
- Suspected overdose or accidental exposure: obtain urgent emergency advice; do not drive the affected person or leave them alone
- A seizure, collapse or severe confusion: seek emergency care
Opioid use disorder can affect relationships, finances, daily responsibilities and family well-being, but experiences vary. Families benefit from clear information, practical support, access to treatment and an overdose-response plan. Blame and assumptions about someone’s character do not help establish a diagnosis or improve care.
How fentanyl addiction affects children
When a parent has opioid use disorder, children may need additional emotional and practical support. The response should depend on the child’s needs and circumstances, including:
- Whether the child has reliable, safe day-to-day care and trusted adults to turn to
- The child’s emotional needs, any immediate safety concerns and access to suitable professional support
Family structure alone does not predict a child’s experience. Trusted adults, stable routines, age-appropriate explanations and access to professional support can help. Where there is an immediate safety concern, seek emergency or local safeguarding assistance. Children should not be expected to manage a parent’s treatment or overdose response on their own.
How fentanyl addiction affects parents
Parents supporting a child with opioid use disorder may experience worry, stress or uncertainty. They can seek their own support, learn how to respond to overdose and discuss boundaries and treatment options with professionals. A parent is not automatically responsible for the condition, and there is no single pattern that describes every family.
How fentanyl addiction affects siblings
Siblings may also need space to discuss their concerns and maintain their own routines and relationships. Family counseling or other support may be useful when appropriate. Neither neglect nor later substance use should be assumed solely because a sibling has opioid use disorder.
Fentanyl-related opioid use disorder is treatable. Care should begin with an assessment of overdose risk, other substance use, physical and mental health, current medicines and the person’s goals. Outpatient, inpatient or residential care may be appropriate depending on individual needs.
Treatment can combine medication for opioid use disorder, overdose prevention, psychological support and continuing care. These elements do not have to follow a universal detox-then-rehabilitation sequence:
Detoxification
Withdrawal management can relieve symptoms when clinically appropriate, but detoxification alone is not recommended as treatment for opioid use disorder. There is no universal seven- to ten-day timetable or requirement for residential detox. Withdrawal can cause distress and problems such as dehydration from vomiting or diarrhea. Severe illness, seizures, confusion or immediate self-harm risk require urgent medical assessment. After reduced use, lower tolerance increases the risk of overdose if opioids are used again.
Medication-Assisted Treatment
Buprenorphine and methadone are evidence-based medications for ongoing opioid use disorder treatment, not simply short-term withdrawal relief. In the United States, naltrexone is another approved option after an adequate opioid-free interval determined by a clinician. Starting buprenorphine or naltrexone at the wrong time can precipitate withdrawal, so initiation requires a clinical plan. Medication choice, access and monitoring depend on the person and local services. Naloxone and overdose-response education should also be offered.
Therapy Options
Psychological and social support can help people address cravings, distress, relationships and practical needs. Such support should be offered alongside medication when appropriate; its unavailability or a person’s decision to decline it should not delay medication treatment. Options include:
- Motivational interviewing can help people explore their goals and choices about treatment.
- Cognitive behavioral therapy can support coping skills and help people address thoughts, behaviors and situations linked to substance use.
- Group or peer support can offer shared experience and practical encouragement; the person should be able to choose a suitable setting.
A qualified clinician should agree a treatment plan with the person and review it over time. Care can include treatment for pain, mental health conditions or other substance use, family support when appropriate, and help with housing or daily responsibilities. No single program guarantees recovery or prevents every return to use.
